Minerva Surgical Announces $30 Million Private Placement of Common Stock Led by Accelmed Partners

Written by Customer Service on December 27, 2022. Posted in Public Companies.

SANTA CLARA, Calif., Dec. 27, 2022 (GLOBE NEWSWIRE) — Minerva Surgical, Inc. (Nasdaq: UTRS) (Minerva Surgical or the Company), a women’s health company focused on the treatment of Abnormal Uterine Bleeding (AUB), announced today that it has entered into a share purchase agreement for the sale of 146,627,565 shares (subject to adjustment for any stock split occurring prior to closing) of its common stock in a private placement, led by Accelmed, with participation by New Enterprise Associates, at an offering price of $0.2046 per share (subject to adjustment for any stock split occurring prior to closing). Following the offering, Accelmed will become the controlling stockholder of Minerva Surgical. Gross proceeds of the private placement are expected to be approximately $30 million, before deducting placement agent fees and other...

PMV Consumer Acquisition Corp. Completes the Redemption of the Class A Common Stock Issued in its IPO

Written by Customer Service on December 27, 2022. Posted in Public Companies.

Palm Beach, FL, Dec. 27, 2022 (GLOBE NEWSWIRE) — PMV Consumer Acquisition Corp. (OTC Pink: PMVC) (“PMV” or the “Company”) announced today the completion of the redemption of its outstanding shares of Class A Common Stock subject to redemption, totaling 2,046,609 shares issued in its IPO (“Class A IPO Shares”), in accordance with the provisions of its charter. Holders representing a total of 2,042,409 shares of the Class A IPO Shares called for redemption elected to receive a pro rata share of the cash, including the interest earned thereon net of interest that may be used by the Company to pay its taxes payable (and not any stock), held in the Company’s IPO Trust Account. The $10.10 per share pro rata amount was calculated by dividing the number of Class A IPO Shares redeemed from each such holder by the total number of outstanding...

Gorilla Technology Group Wraps up Successful 2022 by Entering MENA Region with Security Convergence Offering in Multi-Year, Multi-Million Dollar Deal

Written by Customer Service on December 27, 2022. Posted in Public Companies.

First win in region affirms globalization strategy, initially targeting Europe, the Middle East and North Africa as company accelerates global expansion efforts TAIPEI, Taiwan and NEW YORK, Dec. 27, 2022 (GLOBE NEWSWIRE) — Gorilla Technology Group Inc. (“Gorilla”) (NASDAQ: GRRR), a global provider of AI based edge video analytics, IoT technologies, and cybersecurity, today announced that a government agency of a Middle Eastern country developing Smart Cities has communicated its intent to engage Gorilla to implement an expansive cybersecurity solution for one or more cities under development. Gorilla is negotiating final details, and expects to execute a contract and begin implementation in the first half of 2023. The anticipated project is a strong addition to the Company’s 2023 revenue forecast. This deal represents Gorilla’s...

Credit Acceptance Announces Increase and Extension of Revolving Secured Warehouse Facility and Extension of Asset-Backed Financing

Written by Customer Service on December 27, 2022. Posted in Public Companies.

Southfield, Michigan , Dec. 27, 2022 (GLOBE NEWSWIRE) — Credit Acceptance Corporation (Nasdaq: CACC) (referred to as the “Company”, “Credit Acceptance”, “we”, “our”, or “us”) announced today that we increased the amount of Warehouse Facility V (the “Facility”), one of our revolving secured warehouse facilities, from $125.0 million to $200.0 million. We also extended the date on which the Facility will cease to revolve from December 18, 2023 to December 29, 2025. The maturity of the Facility was also extended from December 16, 2025 to December 27, 2027. The interest rate on borrowings under the Facility has increased from Secured Overnight Financing Rate (“SOFR”) plus 235 basis points to SOFR plus 245 basis points and the servicing fee has decreased from 6.0% to 4.0% of collections on the underlying consumer loans. As of December...

Tiziana Life Sciences Ltd (“Tiziana” or “the Company”) – Interim Results for the Six Months Ended 30 June 2022

Written by Customer Service on December 27, 2022. Posted in Public Companies.

Advancing pipeline of next generation therapeutics and diagnostics for oncology and immune diseases of high unmet need LONDON, Dec. 27, 2022 (GLOBE NEWSWIRE) — Tiziana Life Sciences Ltd (“Tiziana”, NASDAQ: TLSA), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases today announces its interim results for the six months ended 30 June 2022. Highlights during the period: CLINICAL and NON-CLINICAL PROGRAMMES ForalumabTZLS-401 Announced FDA approval for enrollment of a second, Secondary Progressive Multiple Sclerosis (SPMS) patient in under the Individual Patient Expanded Access (EA) Program following favorable clinical results after 6 months of treatment of the first patient in the EA program. Announced initiation of phase 1b clinical trial in Crohn’s disease patients to...

Welsbach Technology Metals Acquisition Corp. Announces Receipt of Deposit Proceeds from Extension Note

Written by Customer Service on December 27, 2022. Posted in Mergers And Acquisitions.

New York, NY, Dec. 27, 2022 (GLOBE NEWSWIRE) — Welsbach Technology Metals Acquisition Corp. (the “Company”), announced today that on December 30, 2022 it issued and sold to Welsbach Acquisition Holdings LLC (the “Sponsor”) a non-interest bearing, unsecured promissory note equal to $772,768.60 (the “Proceeds”), and that such Proceeds were placed on deposit in the Company’s Trust Account on December 23, 2022. As such, in accordance with Article G of the Company’s amended and restated certificate of incorporation, the Company’s time period to consummate a Business Combination has been extended to and including March 30, 2023. Such note would not be repaid in the event that the Company is unable to close a business combination unless there are funds available outside the trust account to do so and would either be paid upon consummation...

Masitinib receives orphan drug status for the treatment of amyotrophic lateral sclerosis in Switzerland

Written by Customer Service on December 27, 2022. Posted in Public Companies.

PRESS RELEASE MASITINIB RECEIVES ORPHAN DRUG STATUS FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) IN SWITZERLAND Paris, December 27, 2022, 7pm CET AB Science SA (Euronext – FR0010557264 – AB) today announces that masitinib has been granted orphan drug status (ODS) by the Swiss Agency for Therapeutic Products (Swissmedic) for the treatment of patients with amyotrophic lateral sclerosis (ALS). As a reminder, masitinib has previously received ODS for ALS from the U.S. Food and Drug Administration (FDA) and from the European Medicines Agency (EMA). This designation provides the sponsor with a series of incentives, including: the possibility of a simplified authorization procedure (Art.13) by Swissmedic fee waivers, and extended document protection period of 15 years. Orphan drug designation in Switzerland is given...

Results of the Extraordinary Shareholders’ Meeting

Written by Customer Service on December 27, 2022. Posted in Public Companies.

Ghent, Belgium, Dec. 27, 2022 (GLOBE NEWSWIRE) — — Press release – regulated information Biotalys (Euronext – BTLS) (the “Company” or “Biotalys”), an Agricultural Technology (AgTech) company protecting crops and food with protein-based biocontrol solutions, held an extraordinary shareholders’ meeting today at 11:00 a.m. CET at the Company’s seat. The legally required presence quorum was reached for the extraordinary shareholders’ meeting. The shareholders approved all items on the agenda of the meeting. All documents relating to the shareholders’ meeting can be consulted on the website of the Company. The minutes will be made available in due course. – ENDS – For further information, please contact Toon Musschoot, Head of IR & CommunicationT: +32 (0)9 274 54 00E: Toon.Musschoot@biotalys.com About...

Ilkka Oyj – Acquisition of own shares on 27 December 2022

Written by Customer Service on December 27, 2022. Posted in Public Companies.

ILKKA OYJ, STOCK EXCHANGE RELEASE, 27 December 2022 at 19:00 EET Ilkka Oyj – Acquisition of own shares on 27 December 2022 At Nasdaq Helsinki Ltd: Date 27 December 2022 Exchange transaction Buy Share trading code ILKKA2 Amount, shares 1,400 Average price/share, EUR 3.6197 Total cost, EUR 5,067.58 The company holds a total of 19,308 of its own shares (ILKKA2) including the shares acquired on 27 December 2022. Detailed information concerning the acquisition is attached to this stock exchange release. On behalf of Ilkka Oyj DANSKE BANK A/S, FINLAND BRANCH Jonathan Nyberg Antti Väliaho Additional information Olli Pirhonen, CEO, Ilkka Oyj, tel. +358 40 766 5418 www.ilkka.com Attachment Ilkka buyback 27.12.2022

CORRECTION — Veeco Announces Upcoming Investor Event

Written by Customer Service on December 27, 2022. Posted in Public Companies.

PLAINVIEW, N.Y., Dec. 27, 2022 (GLOBE NEWSWIRE) — Veeco management will be on site to present and meet with investors at the Lotte New York Palace Hotel in New York City, NY. An earlier press release indicated Veeco’s participation would be virtual. Veeco Instruments Inc. (NASDAQ: VECO) today announced that management is scheduled to present at the 25th Annual Needham Growth Conference at 4:30 PM ET on Tuesday, January 10, 2023 at the Lotte New York Palace Hotel in New York City, NY. Veeco management will also be available to meet in person with investors during the conference. Interested investors should contact their Needham representative to secure a meeting time. The presentation will be broadcast live and can be accessed on the investor relations section of Veeco’s website at ir.veeco.com. A webcast replay will be made...

Day: December 27, 2022

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Cookie Notice